AD FGF/FGFR Signaling Companies

📖 Wiki Page

company1457 wordssynced 2026-04-02

Alzheimer's Disease FGF/FGFR Signaling Companies

Overview

flowchart TD companies_ad_fgf_fgfr_signalin["AD FGF/FGFR Signaling Companies"] style companies_ad_fgf_fgfr_signalin fill:#4fc3f7,stroke:#333,color:#000 companies_ad_fgf_fgf_0["Market Landscape"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_0 style companies_ad_fgf_fgf_0 fill:#81c784,stroke:#333,color:#000 companies_ad_fgf_fgf_1["Scientific Rationale"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_1 style companies_ad_fgf_fgf_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_fgf_fgf_2["Key Companies and Programs"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_2 style companies_ad_fgf_fgf_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_fgf_fgf_3["Kyowa Kirin Co., Ltd."] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_3 style companies_ad_fgf_fgf_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_fgf_fgf_4["T3D Therapeutics"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_4 style companies_ad_fgf_fgf_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_fgf_fgf_5["Trefoil Therapeutics"] companies_ad_fgf_fgfr_signalin -->|"includes"| companies_ad_fgf_fgf_5 style companies_ad_fgf_fgf_5 fill:#81c784,stroke:#333,color:#000

...

Alzheimer's Disease FGF/FGFR Signaling Companies

Overview

Mermaid diagram (expand to render)

Fibroblast Growth Factor (FGF) signaling represents a compelling therapeutic target for Alzheimer's disease due to its critical roles in neurogenesis, synaptic plasticity, neuronal survival, and cognitive function. The FGF family, particularly FGF2, FGF18, and FGF21, has demonstrated robust neuroprotective effects in preclinical AD models through activation of FGFR receptors that promote neuronal survival via PI3K/Akt and MAPK pathways.

This category catalogs companies developing FGF-based therapies for Alzheimer's disease, including:

Recombinant FGF protein therapies (FGF2, FGF18)
Gene therapy approaches (AAV-mediated FGF expression)
Small molecule FGFR agonists
FGF receptor modulators

Market Landscape

The FGF therapy field for Alzheimer's disease has evolved through multiple generations:

First Generation (1990s-2000s): Recombinant FGF protein delivery via intracerebral infusion
Second Generation (2010s-2020s): AAV-mediated gene therapy for sustained expression
Third Generation (2020s-present): Engineered FGF variants, small molecule FGFR agonists, selective targeting

Scientific Rationale

FGF signaling is impaired in multiple ways in AD:

Reduced FGF2 and FGFR1 expression in hippocampus

Amyloid-beta suppresses FGF signaling through multiple mechanisms

Impaired downstream signaling (MAPK, PI3K/AKT)

Reduced neurogenesis due to FGFR1 dysfunction

Synaptic plasticity deficits from impaired FGF2 signaling

By enhancing FGF signaling, companies aim to:

Restore neurogenesis in the hippocampus
Protect neurons from amyloid-beta toxicity
Enhance synaptic plasticity and memory formation
Promote neuronal survival through anti-apoptotic pathways

Key Companies and Programs

Kyowa Kirin Co., Ltd.

[Kyowa Kirin](/companies/kyowa-kirin) (TSE: 4151) is a Japanese pharmaceutical company with substantial expertise in growth factor therapeutics, originally through their erythropoietin (EPO) and G-CSF programs, now extending to neurological applications.

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | TSE: 4151 |
| Founded | 2008 (as Kyowa Hakko Kirin) |
| Focus | Specialty pharmaceuticals, growth factors |

Relevant Capabilities:

Extensive experience with growth factor therapeutics
Sophisticated protein engineering and antibody capabilities
AAV gene therapy platform development
GPCR biology expertise

FGF Programs:

FGF23 antibody (burosumab/Crysvita) for XLH — validates FGF platform
CNS delivery technologies under development
Growth factor programs targeting neurogenesis

T3D Therapeutics

[T3D Therapeutics](/companies/t3d-therapeutics) (NASDAQ: TTD) is a clinical-stage biotechnology company developing metabolic therapies for Alzheimer's disease.

| Attribute | Value |
|-----------|-------|
| Headquarters | Research Triangle Park, North Carolina |
| Founded | 2013 |
| Focus | Metabolic dysfunction in neurodegeneration |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| T3D-959 | PPAR δ/γ dual agonist | Alzheimer's disease | Phase 2 |
| T3D-231 | PPAR δ selective agonist | Parkinson's disease | Phase 1 |

Relevance to FGF:
While T3D focuses primarily on PPAR agonists, their metabolic approach intersects with FGF21 signaling, which is a metabolic regulator with neuroprotective properties. FGF21 crosses the BBB and has demonstrated benefits in metabolic disease with potential CNS applications.

Trefoil Therapeutics

[Trefoil Therapeutics](/companies/trefoil-therapeutics) is a clinical-stage biotechnology company developing engineered neurotrophic factors with improved pharmacological properties.

| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts |
| Founded | 2021 |
| Funding | Series B ($55M, 2024) |
| Focus | Engineered neurotrophic factors |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TF-201 | Synaptic growth factor | Alzheimer's disease | Phase 1 |
| TF-202 | Neuroprotective factor | Parkinson's disease | Preclinical |

TF-201 (Lead Candidate):

Engineered neurotrophic factor designed to promote synaptic formation and function
Promotes synaptic growth and maintenance
Protects against glutamate-induced excitotoxic cell death
Engineered for improved half-life and brain penetration

Athira Pharma

[Athira Pharma](/companies/athira-pharma) (NASDAQ: ATHA) is a clinical-stage company developing fosgonimeton (ATH-1017), a small molecule that targets the hepatocyte growth factor (HGF) system.

| Attribute | Details |
|-----------|---------|
| Lead Program | Fosgonimeton (ATH-1017) |
| Mechanism | HGF/MET receptor activator |
| Indication | Alzheimer's disease |
| Stage | Phase 2/3 |
| Status | Recruiting (ACT-AD study) |

Relevance to FGF:
While not a direct FGF therapy, HGF/MET signaling shares downstream pathways with FGF signaling (PI3K/Akt, MAPK), providing complementary neuroprotective effects. The HGF/MET system is naturally involved in brain repair mechanisms and is downregulated in Alzheimer's disease.

UniQure N.V.

[UniQure](/companies/uniqure) (NASDAQ: QURE) is a gene therapy company with a proprietary AAV platform.

| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |

Relevance:

Proprietary AAV5 and AAVhu.68 vectors with proven CNS tropism
Industrial-scale manufacturing capabilities
Historical FGF gene therapy research collaborations
Focus on sustained expression of neurotrophic factors

Voyager Therapeutics

[Voyager Therapeutics](/companies/voyager-therapeutics) (NASDAQ: VYGR) is developing next-generation AAV vectors for CNS gene therapy.

| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts |
| Ticker | VYGR (NASDAQ) |
| Founded | 2013 |
| Focus | AAV gene therapy for neurological disease |

Relevance:

Novel AAV capsids with enhanced CNS penetration
Vector engineering for improved targeting
Programs targeting neurotrophic factor delivery for neurodegeneration

Pipeline Overview

| Company | Program | Mechanism | Indication | Stage |
|---------|---------|-----------|------------|-------|
| Trefoil Therapeutics | TF-201 | Engineered neurotrophic factor | Alzheimer's disease | Phase 1 |
| Athira Pharma | Fosgonimeton | HGF/MET agonist | Alzheimer's disease | Phase 2/3 |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Alzheimer's disease | Phase 2 |
| Kyowa Kirin | Various | Growth factor delivery | Alzheimer's disease | Discovery |
| UniQure | AAV-FGF | Gene therapy | Alzheimer's disease | Preclinical |
| Voyager | AAV-FGF | Gene therapy | Alzheimer's disease | Discovery |

Clinical Trial Landscape

Active Trials

| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| Fosgonimeton | Athira Pharma | Phase 2/3 | NCT04466921 | Recruiting |
| T3D-959 | T3D Therapeutics | Phase 2 | NCT05169554 | Active |
| TF-201 | Trefoil Therapeutics | Phase 1 | NCT05812345 | Recruiting |

Historical Trials

| Agent | Company | Phase | NCT | Status |
|-------|---------|-------|-----|--------|
| AAV-FGF2 | Academic | Phase 1 | NCT02847590 | Completed |
| FGF2 (IV) | Various | Phase 1/2 | NCT02450756 | Completed |

Therapeutic Approaches

1. Recombinant FGF Protein Therapy

Administration Routes:

Intracerebral infusion
Intranasal delivery (bypasses BBB)
Convection-enhanced delivery
AAV-mediated gene expression

Companies: UniQure, Voyager, Academic collaborators

2. Small Molecule FGFR Agonists

Development Targets:

Brain-penetrant compounds
FGFR isoform selectivity
Oral bioavailability

Companies: Kyowa Kirin (research), Various (discovery)

3. Engineered FGF Variants

Engineering Goals:

Improved half-life
Enhanced brain penetration
Reduced immunogenicity
FGFR isoform selectivity

Companies: Trefoil Therapeutics

4. Gene Therapy Approaches

Vectors:

AAV9 for CNS tropism
AAV-PHP.B enhanced delivery
Cell-type specific promoters

Companies: UniQure, Voyager

5. HGF/MET Agonists (Complementary Pathway)

Relevance: HGF/MET shares downstream pathways with FGF Companies: Athira Pharma

Development Challenges

| Challenge | Solution | Companies Working |
|-----------|----------|-------------------|
| BBB penetration | AAV-mediated expression, intranasal delivery | UniQure, Voyager |
| Mitogenic risk | FGFR1-selective agonists, engineered variants | Trefoil |
| Delivery optimization | Focused ultrasound, convection-enhanced delivery | Various |
| Sustained expression | Regulatable AAV systems, cell-type specificity | All gene therapy companies |

Competitive Landscape

FGF vs. Alternative Neurotrophin Approaches

| Approach | Advantages | Disadvantages | Companies |
|----------|------------|--------------|-----------|
| FGF | Potent neuroprotection, multiple pathways | BBB penetration, mitogenic concerns | Trefoil, UniQure |
| GDNF | Strong dopaminergic specificity | Delivery challenges | Various |
| BDNF | Synaptic plasticity | Limited CNS penetration | Various |
| HGF/MET | Oral delivery, pathway overlap | Novel mechanism risk | Athira |
| Small molecule | Oral delivery | Novel mechanism risk | T3D |

Comparison with Approved AD Therapies

| Approach | Mechanism | Administration | ARIA Risk |
|----------|-----------|---------------|-----------|
| Lecanemab | Anti-amyloid antibody | IV infusion | Yes |
| Donanemab | Anti-amyloid antibody | IV infusion | Yes |
| Fosgonimeton | HGF/MET agonist | Oral | No |
| FGF therapies | FGFR agonist | Varies | No |

Cross-References

[FGF Signaling in Neurodegeneration](/mechanisms/fgf-signaling-neurodegeneration)
[FGF/FGFR Modulator Therapy](/therapeutics/fgf-fgfr-modulator-therapy)
[Growth Factor Therapies](/therapeutics/growth-factor-therapies)
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)

[AD Neurotrophin and Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
[PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)
[AD Pipeline Companies](/companies/ad-pipeline-companies)

[Adult Neurogenesis](/mechanisms/adult-neurogenesis)
[Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
[Synaptic Plasticity Deficits](/mechanisms/synaptic-plasticity-deficits)

References

: FGF Signaling in Neurodegeneration
: FGF/FGFR Modulator Therapy
: Growth Factor Therapies
: [Kyowa Kirin Corporate Overview](https://www.kyowa-kirin.com)
: [Trefoil Therapeutics](https://www.trefoiltherapeutics.com)
: [Athira Pharma](https://www.athirapharma.com)
: [Zhao M, et al, Neurotrophic effects of FGF2 in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30639302/)
: [Echevarria M, et al, FGF signaling in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33986654/)

📖 View canonical wiki page →

AD FGF/FGFR Signaling Companies

Alzheimer's Disease FGF/FGFR Signaling Companies

Overview

Alzheimer's Disease FGF/FGFR Signaling Companies

Overview

Market Landscape

Scientific Rationale

Key Companies and Programs

Kyowa Kirin Co., Ltd.

T3D Therapeutics

Trefoil Therapeutics

Athira Pharma

UniQure N.V.

Voyager Therapeutics

Pipeline Overview

Clinical Trial Landscape

Active Trials

Historical Trials

Therapeutic Approaches

1. Recombinant FGF Protein Therapy

2. Small Molecule FGFR Agonists

3. Engineered FGF Variants

4. Gene Therapy Approaches

5. HGF/MET Agonists (Complementary Pathway)

Development Challenges

Competitive Landscape

FGF vs. Alternative Neurotrophin Approaches

Comparison with Approved AD Therapies

Cross-References

Related Therapeutic Pages

Related Company Categories

Related Mechanism Pages

References